Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.29 USD
+0.03 (1.33%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.27 -0.02 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 261 - 270 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals-May and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Reported no surprises in their Q4/FY 2012 financials
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
KYNAMRO Approval Reduces Risk, In Our View; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage at OUTPERFORM and $10 Price Target - - Standing on the Shoulders of Giants - Advances on Many Fronts
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage at OUTPERFORM and $10 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G